Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis

Neuropsychopharmacology

Volumn 35, Issue 7, 2010, Pages 1520-1530

  Maayan, Lawrence ^a,b   Vakhrusheva, Julia ^b   Correll, Christoph U ^c,d,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antipsychotics; Intervention; Metformin; Pharmacologic; Weight gain; Weight loss

Indexed keywords

AMANTADINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOPENTHIXOL; CLOZAPINE; DEXAMPHETAMINE; DEXFENFLURAMINE; FAMOTIDINE; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; GLUCOSE; IMIPRAMINE; LIPID; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PHENYLPROPANOLAMINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG;

ARTICLE; BODY MASS; BODY WEIGHT; CARBOHYDRATE METABOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GLUCOSE METABOLISM; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT GAIN;

EID: 77952421438     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.21     Document Type: Article

References (55)

1. Allison DB, Mackell JA, McDonnell DD (2003). The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54: 565-567.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
3. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD (2008). Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193: 101-107.
4. Arman S, Sadramely MR, Nadi M, Koleini N (2008). A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 29: 1130-1134.
5. Assuncao SS, Ruschel SI, Rosa Lde C, Campos JA, Alves MJ, Bracco OL et al (2006). Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 28: 270-276.
6. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003). Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 18: 457-461.
7. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N (2004). Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 19: 37-40.
8. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptista E et al (2008a). Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22: 477-495.
9. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A et al (2006). Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51: 192-196.
10. Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S et al (2009). Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42: 14-19.
11. Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E et al (2007). Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93: 99-108.
12. Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S et al (2008b). Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159: 250-253.
13. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE (2002). Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63: 345-348.
14. Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M et al (2003). Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28: 527-529.
15. Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J et al (2009). Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113: 19-26.
16. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB (2003). Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychophar-macol 13: 81-85.
17. Chang CT, Chen YC, Fang JT, Huang CC (2002). Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 15: 398-402.
18. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T et al (2009). Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106: 3907-3912.
19. Citrome L (2008). Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 117: 412-419.
20. Colton CW, Manderscheid RW (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3: A42.
21. Correll CU (2007). Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 12(10 Suppl 17): 12-20 35.
22. Correll CU (2008). Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47: 9-20.
23. Correll CU, Malhotra AK (2004). Pharmacogenetics of antipsycho-tic- induced weight gain. Psychopharmacology (Berl) 174: 477-489.
24. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP et al (2005). Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharma-col 15: 13-21.
25. Faulkner G, Cohn T, Remington G (2007a). Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev (1) CD005148.
26. Faulkner G, Cohn T, Remington G (2007b). Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33: 654-656. (Pubitemid 47343724)
27. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T (1988). A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neurolep-tic-induced obesity. Br J Psychiatry 153: 208-213.
28. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO (2005). Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744-1746.
29. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD et al (2005). A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162: 954-962.
30. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD et al (2007). A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115: 101-105.
31. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R et al (2009). A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia. Acta Psychiatr Scand 119: 457-465.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
33. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T (2000). Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 149: 163-169.
34. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H et al (2008). Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69: 706-711.
35. Kim JH, Yim SJ, Nam JH (2006). A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82: 115-117.
36. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163: 2072-2079.
37. Ko YH, Joe SH, Jung IK, Kim SH (2005). Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28: 169-175.
38. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
39. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
40. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al (2009b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166: 152-163.
41. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004). Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65: 766-771.
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
43. Modell W, Hussar AE (1965). Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA 193: 275-278.
44. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1): 1-93.
45. Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C et al (2005). Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 25: 211-217.
46. Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63: 679-685.
47. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128.
48. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R et al (2007). Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychophar-macology (Berl) 192: 441-448.
49. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R et al (2003). Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160: 297-302.
50. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C et al (2002). Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 159: 1058-1060.
51. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A (2004). The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 14: 332-336.
52. Suppes T, Kelly DI, Perla JM (2005). Challenges in the management of bipolar depression. J Clin Psychiatry 66(Suppl 5): 11-16.
53. Templeman LA, Reynolds GP, Arranz B, San L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmaco-genet Genomics 15: 195-200.
54. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB et al (2008a). Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165: 352-358.
55. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF et al (2008b). Lifestyle intervention and metformin for treatment of anti-psychotic-induced weight gain: a randomized controlled trial. JAMA 299: 185-193.